JAMP-DONEPEZIL TABLETS

Riik: Kanada

keel: inglise

Allikas: Health Canada

Osta kohe

Laadi alla Toote omadused (SPC)
23-03-2015

Toimeaine:

DONEPEZIL HYDROCHLORIDE

Saadav alates:

JAMP PHARMA CORPORATION

ATC kood:

N06DA02

INN (Rahvusvaheline Nimetus):

DONEPEZIL

Annus:

5MG

Ravimvorm:

TABLET

Koostis:

DONEPEZIL HYDROCHLORIDE 5MG

Manustamisviis:

ORAL

Ühikuid pakis:

28/30/250

Retsepti tüüp:

Prescription

Terapeutiline ala:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0131548001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2013-12-27

Toote omadused

                                JAMP-DONEPEZIL TABLETS
(donepezil hydrochloride) Product Monograph
Page 1 of 51
PRODUCT MONOGRAPH
PR
JAMP-DONEPEZIL TABLETS
(donepezil hydrochloride)
Tablets 5 and 10 mg
CHOLINESTERASE INHIBITOR
JAMP PHARMA CORPORATION
1380-203 NEWTON STREET
BOUCHERVILLE, QUEBEC
J4B 5H2
DATE OF REVISION:
MARCH 12, 2015
Submission Control No: 182041
JAMP-DONEPEZIL TABLETS
(donepezil hydrochloride) Product Monograph
Page 2 of 51
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................16
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
.........................................................................
                                
                                Lugege kogu dokumenti
                                
                            

Otsige selle tootega seotud teateid